American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

EUPRAXIA PHARMACEUTICALS INC. (EPRX)

$5.81 -7.78% NASDAQ: EPRX · 15-min delayed

Public · NASDAQ: EPRX
49 employees

Visit website Follow

$388.7MMarket cap

$0Revenue · FY2025

-$38.6MNet income

49Employees

EPRXNASDAQ

2021IPO

About EUPRAXIA PHARMACEUTICALS INC.

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Type: Public · NASDAQ: EPRX
Employees: 49
IPO date: Jun 9, 2021
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: EPRX Nasdaq
SEC CIK: 1581178
LEI: 254900ABKL5YBZMSYH45
SIC: 2834 Pharmaceutical Preparations

Embed this company’s badge

Show Eupraxia Pharmaceuticals Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/eupraxia-pharmaceuticals-inc/"><img src="https://americancompanies.com/badge/eupraxia-pharmaceuticals-inc.svg" alt="Eupraxia Pharmaceuticals Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow EUPRAXIA PHARMACEUTICALS INC. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $0
Net income: -$38.6M
Total assets: $86.2M
Market cap: $388.7M

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: EPRX

$5.81 -7.78%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.31 $9.07

52-week range

Market cap: $388.7M
Shares outstanding: 66.9M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jun 9, 2021

Eupraxia Pharmaceuticals Inc. (EPRX) Stock Price

Reported a net loss of $38.6M in FY2025.
Trading 36% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review EUPRAXIA PHARMACEUTICALS INC..

Write a review

Newsroom

News about EUPRAXIA PHARMACEUTICALS INC.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders GlobeNewswire Inc. · 2026-06-19 · positive Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting GlobeNewswire Inc. · 2026-04-22 · positive Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis GlobeNewswire Inc. · 2026-04-21 · positive Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight GlobeNewswire Inc. · 2026-04-13 · positive Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results GlobeNewswire Inc. · 2026-03-13 · positive Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option Benzinga · 2026-02-20 · positive

News & sentiment via Polygon.io

FAQ

Eupraxia Pharmaceuticals Inc.: frequently asked questions

Is Eupraxia Pharmaceuticals Inc. an American company?

Eupraxia Pharmaceuticals Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Eupraxia Pharmaceuticals Inc. publicly traded?

Yes — Eupraxia Pharmaceuticals Inc. is a publicly traded company. Its stock trades under the ticker symbol EPRX on the NASDAQ.

What does Eupraxia Pharmaceuticals Inc. do?

Eupraxia Pharmaceuticals Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore